Please login to the form below
neurodegenerative disorders
This page shows the latest neurodegenerative disorders news and features for those working in and with pharma, biotech and healthcare.
BioNTech and Weizmann Institute to collaborate at company’s new mRNA centre in Israel
The company’s agreement with the Weizmann Institute will see the partners collaborate on research into areas such as cancer, infectious diseases and neurodegenerative disorders.
Latest news
-
Michael J Fox Foundation awards $4.9m grant to Muna Therapeutics
other neurodegenerative disorders. ... Kv1.3 plays an important role in creating and maintaining neuroinflammation in Parkinson's and other neurodegenerative diseases.
-
Alpha Cognition announces positive results for Alzheimer’s disease treatment
The biopharma, which focuses on developing novel therapies for neurodegenerative disorders, designed the study to demonstrate pharmacokinetic equivalence between 5mg ALPHA-1062 delayed release tablets and 8mg galantamine hydrobromide extended
-
NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
NRG Therapeutics (NRG) and Domainex have announced a collaboration to focus on developing and improving treatment for neurodegenerative diseases. ... The companies will collaborate to develop novel small molecule disease-modifying medicines for the
-
NRG Therapeutics receives £2.68m Innovate UK Award
NRG Therapeutics (NRG) has received the Biomedical Catalyst (BMC) award to help fund research into treatments for Parkinson's disease, motor neurone disease (MND) and other neurodegenerative disorders. ... NRG’s research in mitochondrial biology aims
-
AbbVie acquires Syndesi Therapeutics in $1bn deal
The deal will allow AbbVie to access Syndesi’s research into the potential treatment of cognitive impairment and other symptoms associated with neurodegenerative and neuropsychiatric disorders, including major depressive disorder and ... With AbbVie's
More from news
Approximately 4 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Transforming clinical trials to accelerate drug development
achieved in other high- impact conditions such as cardiac disease, diabetes and neurodegenerative disorders.
-
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
France has a national plan that aims to improve care pathways for patients with neurodegenerative disorders.
-
Deal Watch January 2018
Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which
-
Deal Watch table for October 2013
R&D collaboration and option to acquire. Molecules targeting mitochondrial function to treat genetic, metabolic or neurodegenerative disorders (discovery).
-
Lonafarnib: promising results in first-ever trial for progeria
FTIs are also in very early development in Alzheimer's disease and neurodegenerative disorders: AstraZeneca has a preclinical research programme in neurodegenerative disease therapeutics and OSI 754 is in phase I
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Azafaros expands executive team with three senior hires
Attracting these experienced and skilled executives to the management team of Azafaros is a major step for the company as our lead program AZ-3102 for neurodegenerative lysosomal storage disorders is
-
Pfizer appoints chief scientific officer
Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of
-
Minoyrx Therapeutics appoints chief medical officer
He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders. ... Prior to this, Dr Meya was
-
Chase Pharmaceuticals appoints former Allergan president
As CEO, Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's
-
Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon
phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”.
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
